Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis

drug resistant tuberculosis: gold, glitter and hope

Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis.

Increasing incidence of MDR-TB, long duration of treatment and co-infection with HIV are the significant problems in achieving the eradication of tuberculosis. Bedaquiline is an anti-tuberculosis drug with unique mechanism of action. It selectively inhibits the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis like acti...

Facing extensively drug-resistant tuberculosis--a hope and a challenge.

As of June 2008, a total of 49 countries worldwide reported to the World Health Organization (WHO) at least one case of extensively drug-resistant tuberculosis. Since its first description in March 2006,1 this disease has become the most alarming issue in international tuberculosis control and one that seriously risks compromising the progress observed in many countries over the past decade.2 E...

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman

A woman with extremely drug-resistant tuberculosis treated with a drug regimen including linezolid and bedaquiline during her last 3 weeks of pregnancy gave birth to a child without abnormalities. No fetal toxicities were noted by 2 years after delivery. This drug combination might be safe during the late third trimester of pregnancy.

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid

The current treatment for drug-resistant tuberculosis (TB) is long, complex, and associated with severe and life-threatening side effects and poor outcomes. For the first time in nearly 50 years, there have been two new drugs registered for use in multidrug-resistant TB (MDR-TB). Bedaquiline, a diarylquinoline, and delamanid, a nitromidoxazole, have received conditional stringent regulatory app...